| 000 | 01674 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250517231143.0 | ||
| 264 | 0 | _c20190129 | |
| 008 | 201901s 0 0 eng d | ||
| 022 | _a2210-7711 | ||
| 024 | 7 |
_a10.1007/s11096-018-0692-y _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBindraban, Anita N | |
| 245 | 0 | 0 |
_aDevelopment of a risk model for predicting QTc interval prolongation in patients using QTc-prolonging drugs. _h[electronic resource] |
| 260 |
_bInternational journal of clinical pharmacy _cOct 2018 |
||
| 300 |
_a1372-1379 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Validation Study | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 | _aDecision Support Systems, Clinical |
| 650 | 0 | 4 |
_aDrug-Related Side Effects and Adverse Reactions _xepidemiology |
| 650 | 0 | 4 | _aElectrocardiography |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aLogistic Models |
| 650 | 0 | 4 |
_aLong QT Syndrome _xchemically induced |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aModels, Statistical |
| 650 | 0 | 4 | _aNetherlands |
| 650 | 0 | 4 | _aROC Curve |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aSensitivity and Specificity |
| 700 | 1 | _aRolvink, José | |
| 700 | 1 | _aBerger, Florine A | |
| 700 | 1 | _avan den Bemt, Patricia M L A | |
| 700 | 1 | _aKuijper, Aaf F M | |
| 700 | 1 | _avan der Hoeven, Ruud T M | |
| 700 | 1 | _aMantel-Teeuwisse, Aukje K | |
| 700 | 1 | _aBecker, Matthijs L | |
| 773 | 0 |
_tInternational journal of clinical pharmacy _gvol. 40 _gno. 5 _gp. 1372-1379 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s11096-018-0692-y _zAvailable from publisher's website |
| 999 |
_c28674588 _d28674588 |
||